"We are very pleased that studies across geographies and in both real-world and clinical trial settings continue to support the benefits to patients of the lower-profile SAPIEN XT valve," said Larry L. Wood, Edwards' corporate vice president, transcatheter valve replacement. "This report from the SOURCE XT Registry confirms the positive impact TAVR provides for patients' quality of life and heart function, which is once again profound."

The SOURCE XT Registry, a monitored and adjudicated prospective registry, is studying the use of the Edwards SAPIEN XT valve in a real-world commercial setting, treating high-risk and inoperable patients with severe symptomatic aortic stenosis. The study cited both the baseline and cardiovascular characteristics of the treated patients in confirming their high risk profiles. Despite this patient risk level, the one-year survival post-TAVR was 80.5 percent(1), and freedom from important procedural complications was notable: the study found that stroke occurred in 6.3 percent of patients, and it was reported that 93.8 percent of patients had none/trace or mild paravalvular aortic regurgitation.

The presentation also addressed a segment of the treated patients with a EuroScore of less than 15 percent, which primarily consisted of patients who were deemed inoperable due to conditions such as porcelain aorta, liver disease, frailty, cancer, dialysis and severe pulmonary hypertension.

The SOURCE XT Registry enrolled patients treated with the SAPIEN XT valve in 17 countries between July 2010 and October 2011. Patients were treated using a transfemoral (62.7 percent), transapical (33.3 percent), transaortic (3.7 percent) or subclavian (.3 percent) approach and will be followed out to five years.

The Edwards SAPIEN XT valve is an investigational device not yet available commercially in the United States. It is currently being evaluated in the U.S. in The PARTNER II Trial.

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring, enabling them to save and enhance lives. Additional company information can be found at www.edwards.com.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, Mr. Wood's comments and statements regarding clinical programs. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement.

Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors, including but not limited to, unexpected results of expanded clinical experience and unanticipated effects of regulatory, clinical and quality systems. These factors are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2012.

Edwards, Edwards Lifesciences, the stylized E logo and Edwards SAPIEN XT are trademarks of Edwards Lifesciences Corporation.

(1) All percents for data in this press release are Kaplan-Meier estimates.

— WebWireID175138 —

NeuroStar TMS Therapy was administered to patients as determined by the evaluating physician, consistent with labeled use.  Patients who received benefit from acute NeuroStar TMS Therapy were tapered from their TMS regimen and observed through 52 weeks of follow-up.  Clinical assessments (CGI-Severity of Illness, PHQ-9 and IDS-SR) were obtained at three, six, nine and twelve months.  Concurrent medication use and TMS reintroduction for recurrent symptoms was recorded and summarized during the long-term follow up.
 
Compared with baseline, there was a statistically significant reduction in mean [SD] CGI-S, PHQ-9 and IDS-SR total scores at the end of acute treatment (5.1 [0.9] versus 3.2 [1.5], 18.3 [5.2] versus 9.6 [7.0], and 45.7 [11.0] versus 27.4 [15.8], all P less than 0.0001), which was sustained throughout the 52 week follow-up (3.0 [1.5], 9.4 [7.2], and 27.3 [16.1], all P less than 0.0001), respectively.
 
About Neuronetics, Inc.
Neuronetics, Inc., is a privately-held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses.  Based in Malvern, PA, Neuronetics is the leader in the development of TMS Therapy, a non-invasive form of neuromodulation.  For more information, please visit www.neuronetics.com or www.neurostar.com.
 
NeuroStar®, NeuroStar TMS Therapy® and TMS Therapy® are registered trademarks of Neuronetics, Inc.
 
# # #

53-51043-000 Rev A
 

— WebWireID174957 —

They found that, as women age, their egg cells become riddled with DNA damage and die off because their DNA repair systems wear out. Defects in one of the DNA repair genes—BRCA1—have long been linked with breast cancer, and now also appear to cause early menopause.

'We all know that a woman's fertility declines in her 40s. This study provides a molecular explanation for why that happens,' said Dr. Susan Taymans, Ph.D., of the Fertility and Infertility Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the NIH institute that funded the study. 'Eventually, such insights might help us find ways to improve and extend a woman's reproductive life.'

The findings appear in Science Translational Medicine.

In general, a woman's ability to conceive and maintain a pregnancy is linked to the number and health of her egg cells. Before a baby girl is born, her ovaries contain her lifetime supply of egg cells (known as primordial follicle oocytes) until they are more mature. As she enters her late 30s, the number of oocytes — and fertility — dips precipitously. By the time she reaches her early 50s, her original ovarian supply of about 1 million cells drops virtually to zero.

Only a small proportion of oocytes — about 500 — are released via ovulation during the woman's reproductive life. The remaining 99.9 percent are eliminated by the woman's body, primarily through cellular suicide, a normal process that prevents the spread or inheritance of damaged cells.

The scientists suspect that most aging oocytes self-destruct because they have accumulated a dangerous type of DNA damage called double-stranded breaks. According to the study, older oocytes have more of this sort of damage than do younger ones. The researchers also found that older oocytes are less able to fix DNA breaks due to their dwindling supply of repair molecules.

Examining oocytes from mice, and from women 24 to 41 years old, the researchers found that the activity of four DNA repair genes (BRCA1, MRE11, Rad51 and ATM) declined with age. When the research team experimentally turned off these genes in mouse oocytes, the cells had more DNA breaks and higher death rates than did oocytes with properly working repair systems.

The research team's findings stemmed from their initial focus on BRCA1, a DNA repair gene that has been closely studied for nearly 20 years because defective versions of it dramatically increase a woman's risk of breast cancer.

Using mice bred to lack the BRCA1 gene, the NICHD-supported scientists confirmed that a healthy version of BRCA1 is vital to reproductive health. BRCA1-deficient mice were less fertile, had fewer oocytes, and had more double-stranded DNA breaks in their remaining oocytes than did normal mice.

Abnormal BRCA1 appears to cause the same problems in humans—the team's studies suggest that if a woman's oocytes contain mutant versions of BRCA1, she will exhaust her ovarian supply sooner than women whose oocytes carry the healthy version of BRCA1.

Together, these findings show that the ability of oocytes to repair double-stranded DNA breaks is closely linked with ovarian aging and, by extension, a woman's fertility. This molecular-level understanding points to new reproductive therapies. Specifically, the scientists suggest that finding ways to bolster DNA repair systems in the ovaries might lead to treatments that can improve or prolong fertility.

Senior author Kutluk Oktay, M.D., of New York Medical College (NYMC), in Rye and Valhalla, collaborated with colleagues at NYMC and researchers at Istanbul Bilim University, Turkey; Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York; and Yeshiva University, New York.

The work was supported by grants HD53112 and HD61259.

About the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): The NICHD sponsors research on development, before and after birth; maternal, child, and family health; reproductive biology and population issues; and medical rehabilitation. For more information, visit the Institute's website at http://www.nichd.nih.gov/.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

— WebWireID174958 —

"Many researchers have been working on such a diagnostic test for a long time — for me, it has been 20 years," says lead investigator Massimo Raimondo, M.D., a gastroenterologist at Mayo Clinic in Florida. "But for the first time, we have found a very strong candidate molecular marker.

"We all want a foolproof method to detect pancreatic cancer in our patients so that we can deliver appropriate therapy, as soon as possible," Dr. Raimondo adds. "While we know more research is needed, including validation of our findings, we can't help but be excited about this advance."

Pancreatic cancer and chronic pancreatitis both produce the same signs of disease in the pancreas, such as inflammation, but cancer in the organ is a life-threatening disorder that must be treated immediately and aggressively, Dr. Raimondo says.

The research team, which included investigators from Mayo Clinic in Rochester, Minn., tested a method that examined secretions from the pancreas during a routine upper endoscopy.

In patients suspected of having chronic pancreatitis or pancreatic cancer, physicians use a thin flexible scope to examine the upper digestive tract. In this study, during such routine endoscopies, physicians injected the substance secretin intravenously, to fool the pancreas into believing the stomach contains food that the pancreas needs to help digest. The organ then secreted juice rich in enzymes to help break down the food, along with exfoliated cells, and the researchers collected some of this fluid.

They examined the juice for markers that might distinguish the two disorders, and discovered that the altered gene CD1D, as a single marker, detected 75 percent of patients later diagnosed with pancreatic cancer, but was present in only 9 percent of patients with chronic pancreatitis.

"CD1D performed much better than any other pancreatic secretion marker previously tested in identifying pancreatic cancer," Dr. Raimondo says.

The research team is working on further improving the accuracy of this promising molecular diagnostic approach.

"These results on Dr. Raimondo's carefully collected samples are really exciting and have clear practice-changing implications," says co-author David Ahlquist, M.D., who led the collaborating laboratory team at Mayo Clinic in Rochester. Diagnostic accuracy well above 90 percent is possible, he says.

When such a biomarker test is perfected, it could be used not only to distinguish pancreatic cancer from chronic pancreatitis, but, potentially, as a screening test for patients at high risk for pancreatic cancer, Dr. Raimondo says.

The study was funded by grants from the Charles Oswald Foundation.

###

About Mayo Clinic

Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit MayoClinic.com or MayoClinic.org/news.

Journalists can become a member of the Mayo Clinic News Network for the latest health, science and research news and access to video, audio, text and graphic elements that can be downloaded or embedded.

— WebWireID174881 —

— WebWireID174521 —

Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center was first facility in the United States to use the nMARQ™ System to treat paroxysmal Afib as part of the clinical study. Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, performed the first case in the United States, and was among the first to use this new catheter in Europe. 'I am encouraged by the possibilities of this new system,' said Dr. Natale. 'This technology could provide another tool to more effectively treat patients with paroxysmal Afib.'

'We are excited about the start of the pivotal U.S. clinical trial for this innovative new technology,' said Shlomi Nachman, Worldwide President, Biosense Webster, Inc. 'By combining the multi-ablation capability of nMARQ™ System with the proven irrigation technology and the unparalleled mapping accuracy of the Carto® 3 System, this new platform has been designed to reduce procedure time and complexity.'

The nMARQ™ System consists of a multi-electrode, irrigated catheter ablation system. Each nMARQ™ Catheter has 10 irrigation holes per electrode completely surrounding the electrodes. The reMARQable trial will enroll approximately 400 patients at up to 50 sites in the U.S. The study is being conducted under an FDA-approved Investigational Device Exemption, and the new catheter is not available in the United States outside of the reMARQable study. Further information is available at: http://clinicaltrials.gov/ct2/show/NCT01824394?term=remarqable&rank=1.

About AF and cardiac ablation
Atrial Fibrillation is the most prevalent arrhythmia, and is a leading cause of stroke among people 65 years and older. Worldwide, it is estimated that 20 million people have AF, yet only ~130,000 are treated with ablation every year. The public health implications of AF are a growing concern because those with AF are at an increased risk of morbidity and mortality as well as a reduced quality of life.

Most patients with AF today are treated with anti-arrhythmic drugs (AADs), even though about half of them are refractory to these drugs. During cardiac ablation, energy is delivered through the catheter to those areas of the heart muscle causing the abnormal heart rhythm. This energy 'disconnects' the pathway of the abnormal rhythm. Cardiac ablation is commonly used for 'simple' arrhythmias, like Wolff-Parkison-White Syndrome and atrioventricular nodal re-entry tachycardia (AVNRT), and is increasingly being used for more complex arrhythmias like ventricular tachycardia and atrial fibrillation. ThermoCool® Navigation Catheters are approved for drug refractory recurrent symptomatic paroxysmal atrial fibrillation, when used with Carto® Systems (excluding NaviStar® RMT ThermoCool® Catheter).

About Biosense Webster, Inc.
Biosense Webster, Inc., part of the Johnson & Johnson Family of Companies, pioneered EP diagnostic catheters more than 20 years ago and continues to lead the industry as an innovative provider of advanced cardiac diagnostic, therapeutic, and mapping tools. As the leader in EP navigation systems and ablation therapy, Biosense Webster, Inc. has technology that includes the largest installed base of cardiac mapping navigation systems worldwide in leading hospitals and teaching institutions. For more information about Biosense Webster and its products, please visit: www.biosensewebster.com.

Dr. Natale is compensated for his services as a member of the company's scientific advisory board and provides other consulting services.

The US nMARQ™ Catheters and nMARQ™ Generator are approved for investigational use only and are not for sale in the United States. nMARQ™ Catheters and nMARQ™ Generator are approved for sale only in some countries-part of the European Union, Middle East and Africa Region.

— WebWireID174504 —

About Neuronetics, Inc.
Neuronetics, Inc., is a privately-held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses.  Based in Malvern, PA, Neuronetics is the leader in the development of NeuroStar TMS Therapy, a non-invasive form of neuromodulation.  Neuronetics was created as a spin-out of The Innovation Factory, a medical device incubator in Duluth, GA.  For more information, please visit www.neuronetics.com and www.neurostar.com.  

53-51041-000 Rev A

— WebWireID174443 —

• Arul Chinnaiyan, MD, PhD, S.P. Hicks Endowed Professor of Pathology at the University of Michigan Center for Computational Medicine and Bioinformatics. He is also the Director of the Michigan Center for Translational Pathology. Dr. Chinnaiyan's research focuses on functional genomics, proteomic, and bioinformatic approaches to study cancer and was selected to be the Co-Leader of Stand Up To Cancer's (SU2C) Prostate Cancer Dream Team.  He is the key innovator behind the discovery of PCA3 and TEMPRESS to improve prostate cancer diagnosis and leads the research efforts of MI-ONCOSEQ.

• Jay L. Hess, MD, PhD, MHSA, is the Carl Weller Professor and Chair of the Department of Pathology at the University of Michigan and the founding Chair of Paradigm. He has served as Professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine as well as Director of Hematopathology for the Penn Health System. He was the Co-Director of the hematologic malignancies program at Philadelphia's Abramson Cancer Center. Dr. Hess is a board-certified hematopathologist and a specialist in the genetic and molecular changes that lead to cancer.

• Maha Hussain, MD, Professor of Medicine and Urology at the University of Michigan. She is also the Associate Director for Clinical Research at the University of Michigan Comprehensive Cancer Center, the Co-Leader of its Prostate Cancer/GU Oncology Program and the Associate Chief for Clinical Research at the Division of Hematology/ Oncology. Dr. Hussain is an expert in genitourinary malignancies with a focus on prostate and bladder cancers.

• John Niederhuber, MD, is the Chief Executive Officer at Inova Translational Medicine Institute. He also serves as Co-Director of the Johns Hopkins Clinical Research Network. Dr. Niederhuber is the former Director of the National Cancer Institute and has dedicated his four-decade career to the treatment and study of cancer. As a surgeon, Dr. Niederhuber's clinical emphasis is on gastrointestinal cancer, hepatobiliary (liver, bile duct, and gallbladder) and breast cancers.  Dr. Niederhuber was elected to the Institute of Medicine in recognition of his outstanding scientific accomplishments and commitment to service in health science.

• Robert Penny, MD, PhD, is the Founder and Chief Executive Officer of Paradigm.  He is also the Co-Founder and Chief Executive Officer of IGC. He introduced the first commercial gene expression tests in oncology in the United States and has been a leader in The Cancer Genome Atlas (TCGA) project.   He has been instrumental in bringing molecular pathways into the practice of oncology through the Molecular Profiling Institute and AmeriPath and was recently awarded the 2012 Distinguished Patient Care Award from the College of American Pathologists.

— WebWireID174329 —

'These presentations confirm that the rtx1* is becoming an indispensable tool for doctors that need to study the retina at a level of detail that remains invisible to other imaging products' states Nicolas Chateau, CEO of Imagine Eyes. 'What we're seeing is comparable to the revolutions fostered by the advent of OCT where the early results sought to define the clinical applications of those technologies. Much of what is being presented either validates that what is seen with the rtx1 is coherent with accepted anatomical data or highlights the rtx1's unique contribution to visualizing changes in retinal morphology caused by specific diseases. The ensemble of the body of work is as impressive as it is promising.'

'We are very happy to see that our customers have taken full advantage of the new software features we delivered last year' notes Xavier Levecq, Imagine Eyes' CTO. 'In addition to enhancing the software interface's ergonomics, we provided significantly improved image processing features and quantitative image analysis tools. The latter have enabled customers to measure cone density, inter-cone spacing and cone mosaic regularity metrics – all of which are displayed both as descriptive statistics and as easy to interpret color charts.'

'The new processing algorithm has vastly improved the image quality of the cone mosaic.  We are even seeing what we think might be rods in some cases' notes Mark Pennesi, Assistant Professor, Director of Ophthalmic Imaging at the Casey Eye Institute at the Oregon Health & Science University in Portland, OR.

'As a member of Imagine Eyes' Medical Advisory Board, I have watched the rtx1 develop from an early-stage prototype into a commercial product' remarks José Sahel, Chairman of Ophthalmology at France's Quinze-Vingts National Eye Hospital. 'The outstanding results being presented by groups from around the world that use the rtx1 are sure to inspire many others to incorporate the product's unique functionalities into their clinical research.'

To see a list of presentations at the 2013 annual meeting of the Association for Research in Vision and Ophthalmology in Seattle from May 5-9 2013, please visit http://www.imagine-eyes.com/ARVO/. For a list of presentations at the French Ophthalmology Society (Société Française d'Ophtalmologie 'SFO') annual meeting in Paris from May 11-14, please visit http://www.imagine-eyes.com/SFO/.

To see a live demonstration of the rtx1 Adaptive Optics Retinal Camera*, visit Imagine Eyes at ARVO-ISIE on stand 8, at the ARVO annual meeting exhibit on stand 1115 or at the SFO annual meeting on the Sanotek stand F16. For more information, please visit www.imagine-eyes.com or call +33 (0)1 64 86 15 66.

#####

About Imagine Eyes – Imagine Eyes develops ophthalmic instruments that analyze the eye at the microscopic scale. Conceived from a revolutionary technology, adaptive optics, its products enables cellular-level retinal imaging, precision measurement of the eyes' refractive errors and vision simulation. Founded in 2003 in Orsay, France by photonics and ophthalmic industry specialists, the company is ISO 9001 and 13485 certified. It maintains its position as a technology leader thanks to its intensive R&D program, broad portfolio of patents and the marketing of cutting-edge products that have been rapidly adopted by its customers.

* CE Marked and Shonin approved. The rtx1 has not received FDA clearance.

— WebWireID174128 —

"The results were very surprising,' said Ling-Gang Wu, Ph.D., a scientist at NIH's National Institute of Neurological Disorders and Stroke. 'Like many scientists we thought SNAREs were only involved in fusion."

Every day almost 100 billion nerve cells throughout the body send thousands of messages through nearly 100 trillion communication points called synapses. Cell-to-cell communication at synapses controls thoughts, movements, and senses and could provide therapeutic targets for a number of neurological disorders, including epilepsy.

Nerve cells use chemicals, called neurotransmitters, to rapidly send messages at synapses. Like pellets inside shotgun shells, neurotransmitters are stored inside spherical membranes, called synaptic vesicles. Messages are sent when a carrier shell fuses with the nerve cell's own shell, called the plasma membrane, and releases the neurotransmitter 'pellets' into the synapse.

SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) are three proteins known to be critical for fusion between carrier shells and nerve cell membranes during neurotransmitter release.

"Without SNAREs there is no synaptic transmission," said Dr. Wu.

Botulinum toxin, or Botox, disrupts SNAREs. In a study published in Cell Reports, Dr. Wu and his colleagues describe how they used Botox and similar toxins as tools to show that SNAREs may also be involved in retrieving message carrier shells from nerve cell membranes immediately after release.

To study this, the researchers used advanced electrical recording techniques to directly monitor in real time carrier shells being fused with and retrieved from nerve cell membranes while the cells sent messages at synapses. The experiments were performed on a unique synapse involved with hearing called the calyx of Held. As expected, treating the synapses with toxins reduced fusion. However Dr. Wu and his colleagues also noticed that the toxins reduced retrieval.

For at least a decade scientists have known that carrier shells have to be retrieved before more messages can be sent. Retrieval occurs in two modes: fast and slow. A different group of molecules are known to control the slow mode.

"Until now most scientists thought fusion and retrieval were two separate processes controlled by different sets of molecules," said Dr. Wu.

Nevertheless several studies suggested that one of the SNARE molecules could be involved with both modes.

In this study, Dr. Wu and his colleagues systematically tested this idea to fully understand retrieval. The results showed that all three SNARE proteins may be involved in both fast and slow retrieval.

"Our results suggest that SNAREs link fusion and retrieval," said Dr. Wu.

The results may have broad implications. SNAREs are commonly used by other cells throughout the body to release chemicals. For example, SNAREs help control the release of insulin from pancreas cells, making them a potential target for diabetes treatments. Recent studies suggest that SNAREs may be involved in neurological and psychiatric disorders, such as schizophrenia and spastic ataxia.

"We think SNARES work like this in most nerve cell synapses. This new role could change the way scientists think about how SNAREs are involved in neuronal communication and diseases," said Dr. Wu.

For more information about research conducted at NIH's NINDS, please visit: http://intra.ninds.nih.gov/

NINDS is the nation's leading funder of research on the brain and nervous system. The NINDS mission is to reduce the burden of neurological disease – a burden borne by every age group, by every segment of society, by people all over the world.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH...Turning Discovery Into Health®
Reference

Xu J et al. 'SNARE proteins synaptobrevin, SNAP-25 and syntaxin are involved in rapid and slow endocytosis at synapses.' Cell Reports, May 2, 2013. DOI: 10.1016/j.cellrep.2013.03.010

— WebWireID174078 —

— WebWireID173922 —

Mr. Adams will oversee all human resources and recruiting functions for Touchpoint including employee relations, talent and recruitment, learning and development, and compensation and benefits. As a member of the Touchpoint executive team, he will act as a strategic consultant on industry trends, while providing leadership, support, and vision to help foster opportunities for business growth.

Mr. Adams joins Touchpoint from Pfizer where he served as Vice President, Human Resources, and previously held the position of Chief Human Resources Officer at Geneva Global, Inc. His career history also includes Director, Global Functions Human Resources Operations for Hewlett-Packard, as well as Assistant Vice President, University Relations Staffing for Cigna.

'Andrew has tremendous experience and an impressive track record of success. With his strategic insight and leadership, he will play an important role within the organization as we continue to grow and design new solutions for our clients,' said Rick Keefer, president and CEO of Publicis Touchpoint Solutions.

###

For business inquiries, please contact Touchpoint Business Development, at (215) 525-9810 or eMail Impact@TouchpointSolutions.com .

About Publicis Touchpoint Solutions, Inc.
Publicis Touchpoint Solutions designs and implements customized, cross-channel, healthcare sales, service, and clinical teams. From in field to inside and from promotional to clinical, Publicis Touchpoint Solutions centers-of-excellence include field sales and service, live video detailing, inside credentialed sales specialists, inside sales and service, clinical health educators, and medical science liaisons. A wide range of vital support solutions—each of which serves all of the company's message delivery channels—includes recruiting, training, performance management, operations, data/analytics, and compliance. Publicis Touchpoint Solutions provides the human touch to precision cross-channel messaging delivered at the right time and through the right channels to achieve maximum impact. Publicis Touchpoint Solutions is a member of the Publicis Healthcare Communications Group.

Website: www.TouchpointSolutions.com
Twitter: http://twitter.com/pTouchpoint
LinkedIn: http://linkd.in/pTouchpoint

About Publicis Healthcare Communications Group
Publicis Healthcare Communications Group (PHCG) is the largest health-oriented agency network in the world. A division of Publicis Group, PHCG manages top-tier agencies specializing in promoting innovative solutions in advertising, medical education, message delivery, digital, media, market access, and medical and scientific affairs. PHCG is dedicated to delivering ideas of purpose that compel action, change lives, and amplify business outcomes. With nearly 5,000 employees, PHCG manages 12 agency brands through 58 offices located in 11 countries. PHCG's global brands are Saatchi & Saatchi Health, Publicis Life Brands, Digitas Health, Razorfish Healthware, Publicis Health Media, and Publicis Touchpoint Solutions.

Website: www.publicishealthcare.com
Facebook: www.facebook.com/publicishealthcare

— WebWireID173906 —

For so many, the experience of having blood drawn is a dreaded event. While the skill of the doctor or nurse administering the procedure is a key factor in keeping the patient comfortable, the use of a proper blood drawing chair or donor bed can make an incredible difference as well. There is an extensive selection of chairs, mobile lounges, beds, and even infant stations available at eMedicalShops.com, all of which are designed with the patients' comfort and overall durability as a top priority. On the site you will even find equipment such as a bariatric step stool which makes it even easier for patients to get in and out of the donor beds.

While focusing on patient comfort is undoubtedly of utmost importance, it is also true that doctor's visits can be physically stressful not only for the patient, but for the doctors and medical providers themselves. Having the right equipment, such as the chairs and beds previously mentioned, and also height adjustable carts (featured at: http://emedicalshops.com/emedicalcarts/adjustable-height) can ensure that doctors and nurses are able to have the necessary equipment for any given procedure available at the ideal height. There are also a variety of stools available (featured at: http://emedicalshops.com/emedicalchairs/stools), including an adjustable hydraulic surgeons stool, that are all designed to be both comfortable and durable over many years of use.

In addition to 'Today's Specials' which are listed on the homepage, two current feature promotions include:

• A savings of $400 on a portable blood donor bed when you purchase a lot of 6. Please visit the following link for more details: http://emedicalshops.com/chairs/donor-beds/ja2018-6p-mobile-lounge-chair-bundle/
• A savings of $150 on the best phlebotomy chairs available. All four models are featured here: http://emedicalshops.com/emedicalchairs/quick-ship/, and each comes with a 5-Year frame warranty and ships within 24 hours!

— WebWireID173873 —

Stijn van de Vyver received the award for his PhD research titled 'Rethinking the design of heterogeneous catalysts for the conversion of cellulose', which he conducted at the Katholieke Universiteit Leuven under the supervision of Professor Bert Sels. An international judging committee selected Stijn van de Vyver as winner out of four nominated PhD scientists.

The award was presented to van de Vyver by DSM's CTO Marcel Wubbolts during the combined 9th European Congress on Chemical Engineering and 2nd European Congress on Applied Biotechnology ('ECCE9/ECAB2') on 23 April 2013.

In his PhD work Stijn van de Vyver has made important accomplishments in the catalytic conversion of cellulose. He drastically improved conversion rates by increasing the accessibility of the catalytic centers, using carbon nano-fibers and hyper-branched polymers amongst others as catalyst support.

The jury indicated that van de Vyver's research stood out through its scientific excellence, which was demonstrated by a large number of publications in high ranking journals and patents. The topic of his research is potentially of high economic impact. The jury especially expressed their admiration for the unorthodox and daring approach that van de Vyver has taken in a challenging field. They appreciated the great originality of his thesis.

Nominees and second prize winners were:

-Jing Wu, Eindhoven University of Technology. PhD Supervisor: Professor Cor Koning
PhD thesis title: Novel isohexide-based building blocks and step-growth polymers
-Andreas Posch, Vienna University of Technology. PhD Supervisor: Professor Christoph Herwig
PhD thesis title: Shaping sustainable manufacturing for filamentous fungi – Novel tools for efficient morphological and physiological bioprocess characterization
-Somnath Kadam, Delft University of Technology. PhD Supervisors: Professor Andrzej Stankiewicz/Dr. Herman Kramer
PhD thesis title: Towards a sustainable crystallization process through in situ monitoring and system characterization

The theme of the award was 'Shaping Sustainable Manufacturing' and it was focused on applications in the fields of Chemical Engineering and Applied Biotechnology. From the total number of nominations received, four candidates were selected for the final judging round. These four candidates presented their research in a short lecture during a special DSM Symposium on Sustainable Manufacturing held at the congress in The Hague, the Netherlands on 22 April 2013. A judging committee of leading scientists selected the winner. Marcel Wubbolts presented the award following his keynote lecture 'Sustainable innovations for a changing world'.

Marcel Wubbolts commented: 'Sustainability is the core value of DSM. We believe we have to embrace a People-Planet-Profit based approach to doing business. This is why we have chosen the Shaping Sustainable Manufacturing theme for this edition of our Science and Technology Awards. The collaboration with the ECCE9/ECAB2 congress provided an excellent venue. This congress brings together people from the different fields of chemical engineering and applied biotechnology and therefore is an excellent place to discuss novel approaches.'

The DSM Science & Technology Awards are part of the DSM Bright Science Awards Program. They seek to recognize and reward outstanding young researchers (PhD students and those who have recently obtained their PhD) for innovative research with clear application potential. The award is granted in three different regions: Europe, the Americas and Asia. The award events are organized in cooperation with major scientific conferences in these regions. DSM has a long tradition of more than 25 years of granting awards for excellence in PhD research.

— WebWireID173775 —